Literature DB >> 19546367

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Guillermo Garcia-Effron1, Samuel Lee, Steven Park, John D Cleary, David S Perlin.   

Abstract

Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced susceptibility phenotype. Sequence alignments showed that 11 out of the 13 mutants harbored a mutation in FKS1 or FKS2 not previously implicated in echinocandin reduced susceptibility in C. glabrata. A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-beta-D-glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme. These mutations were also found to reduce the catalytic efficiency of the enzyme (Vmax) and to influence the relative expression of FKS genes. In view of the association of FKS mutations and reduced susceptibility of 1,3-beta-D-glucan synthase, an evaluation of the new CLSI echinocandin susceptibility breakpoint was conducted. Only 3 of 13 resistant fks mutants (23%) were considered anidulafungin or micafungin nonsusceptible (MIC > 2 microg/ml) by this criterion. In contrast, most fks mutants (92%) exceeded a MIC of >2 microg/ml with caspofungin. However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of > or = 2 microg/ml for the three echinocandin drugs. As has been observed with Candida albicans, the kinetic inhibition parameter 50% inhibitory concentration may be a better predictor of FKS-mediated resistance. Finally, the close association between FKS1/FKS2 hot spot mutations provides a basis for understanding echinocandin resistance in C. glabrata.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546367      PMCID: PMC2737881          DOI: 10.1128/AAC.00443-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

Review 2.  Fungal beta(1,3)-D-glucan synthesis.

Authors:  C M Douglas
Journal:  Med Mycol       Date:  2001       Impact factor: 4.076

3.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

4.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 5.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Expert Opin Investig Drugs       Date:  2003-08       Impact factor: 6.206

Review 6.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

7.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

9.  Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 10.  Caspofungin: the first in a new class of antifungal agents.

Authors:  Nicholas A Kartsonis; Jennifer Nielsen; Cameron M Douglas
Journal:  Drug Resist Updat       Date:  2003-08       Impact factor: 18.500

View more
  135 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.

Authors:  Elena De Carolis; Antonietta Vella; Ada R Florio; Patrizia Posteraro; David S Perlin; Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 3.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

4.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

5.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

6.  Enhanced Efflux Pump Activity in Old Candida glabrata Cells.

Authors:  Somanon Bhattacharya; Bettina C Fries
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

7.  Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.

Authors:  Ana Alastruey-Izquierdo; Alicia Gómez-López; Maiken C Arendrup; Cornelia Lass-Florl; William W Hope; David S Perlin; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

8.  Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Authors:  Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R Motyl; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

9.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.